Conditions - Diabetes In Control

SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes

Oct 3, 2020 Cardiology, GLP-1 Agonist Therapy Center, Paid, SGLT-2 Therapy Center, Type 2 Diabetes

Cardiovascular events decline for patients using which antidiabetic medication?

Research Highlights Combination Canagliflozin plus Liraglutide Effects on HBA1c

Sep 29, 2020 GLP-1 Agonist Therapy Center, SGLT-2 Therapy Center, Type 2 Diabetes

The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.

The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors

Sep 26, 2020 Mental Health, Pediatrics, Type 2 Diabetes

Is the risk as substantial as was initially reported?

Diabetes and Subsequent Weight Loss Linked to an Increased Risk of Pancreatic Cancer

Sep 26, 2020 Oncology, Paid, Type 2 Diabetes

The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss.

The Relationship Between Aerobic Exercise Capacity and Cardiac Dysfunction In T2D

Sep 22, 2020 Cardiology, Exercise, Paid, Physical Activity, Type 2 Diabetes

In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure.

Possible Link Connecting COVID-19 and New-Onset Diabetes

Sep 22, 2020 Prediabetes, Type 2 Diabetes

CoviDIAB Registry will explore why COVID-19 can increase complications in people with pre-existing diabetes, and may also be driving new cases.

Adding An SGLT-2 Earlier To A Treatment Plan Yields Positive A1c Levels

Sep 22, 2020 Blood Glucose Control, SGLT-2 Therapy Center, Type 2 Diabetes

If dapagliflozin is the second medication prescribed to the patient after the first-line treatments of metformin or sulfonylurea, it has a greater impact.